ORMP Stock Analysis: Buy, Sell, or Hold?
ORMP - Oramed Pharmaceuticals Inc.
$4.81
0.02 (0.42%)
▲
5d:
+7.37%
30d:
+15.62%
90d:
+9.82%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ORMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORMP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORMP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORMP is currently trading at $4.81, which is considered extended relative to its 30-day fair value range of $4.01 to $4.53.
Technical Outlook: Technically, ORMP is in a uptrend. The price is approaching resistance at $4.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+29.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORMP is in a uptrend. The price is approaching resistance at $4.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+29.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.01 -
$4.53
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+6.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.9% below Wall St target ($6.25)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.01 -
$4.53
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.16
Resistance Level
$4.94
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Wall Street Target
$6.25
(+29.9%)
Revenue Growth (YoY)
-100.0%
Earnings Growth (YoY)
493.5%
Share & Embed Analysis
Last updated: August 21, 2026 11:58 PM ET
Data refreshes hourly during market hours. Next update: 12:58 AM
Data refreshes hourly during market hours. Next update: 12:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
